Minoryx Therapeutics
Edit

Minoryx Therapeutics

http://www.minoryx.com/
Last activity: 10.11.2022
Categories: WebsiteMedTechDrugDevelopmentBioTech
Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, selective PPARγ agonist, is currently being evaluated in X-ALD and Friedreich’s Ataxia. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011, has operations in Spain and Belgium and has raised a total of €50M through Series A & B financing rounds.
Followers
3.15K
Mentions
38
Location: Spain, Catalonia, Mataró
Employees: 11-50
Total raised: $106.01M
Founded date: 2011

Investors 9

Funding Rounds 5

DateSeriesAmountInvestors
07.06.2022Series C$55MFund+
26.09.2018Series B$25.02M-
14.10.2015Series A$22.26M-
23.01.2015-$1.79MCaixa Capi...
04.04.2013-$1.94M-

Mentions in press and media 38

DateTitleDescriptionSource
10.11.2022Minoryx y Neuraxpharm se alían para ofrecer una nueva terapi...09/11/2022 Nota de prensa MINORYX Y NEURAXPHARM SE ALÍAN PARA OFRECER UNA NUEVA TERAPIA A LOS PACI...webcapital...
20.09.2022Minoryx‘s Marketing Authorization Application for its lead c...Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA ...fundplus.b...
07.06.2022Minoryx raises €51 million to support Marketing Authorizatio...Minoryx Therapeutics, a Phase 3 stage biotech company focused on the development of treatments for o...startupsre...
31.05.2022Minoryx Therapeutics closes €51M Series C round co-led by Co...31/05/2022 Press release YSIOS CAPITAL JOINS ITS PORTFOLIO COMPANY. MINORYX THERAPEUTICS, €51 MILL...webcapital...
31.05.2022Minoryx Raises EUR 51M in Series C FundingMinoryx Therapeutics, a Mataró, Barcelona, Spain-based Phase 3 stage biotech company focused on the ...finsmes.co...
31.05.2022Minoryx raises €51 million to support Marketing Authorizatio...Funds will support the marketing authorization review process for male patients with AMN and launch ...fundplus.b...
31.05.2022Bouncing back from late-phase fail, Minoryx pockets €51M to ...Minoryx has persuaded investors to overlook the failure of its phase 2/3 clinical trial, enabling it...fiercebiot...
31.05.2022Minoryx cierra una ronda Serie C de €51M coliderada por Colu...31/05/2022 Nota de prensa MINORYX CONSIGUE €51 MILLONES PARA FINANCIAR LA SOLICITUD DE AUTORIZACIÓ...webcapital...
03.11.2021Additional data from Minoryx’s Phase 2/3 ADVANCE clinical tr...Mataró, Barcelona, Spain, November 3, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech ...fundplus.b...
30.10.2020El BEI proporciona €25M a Minoryx para apoyar el desarrollo ...30/10/2020 Nota de prensa EL BANCO EUROPEO DE INVERSIONES PROPORCIONA €25M A MINORYX PARA APOYAR E...webcapital...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In